Munir Pirmohamed

56.6k total citations · 10 hit papers
601 papers, 34.5k citations indexed

About

Munir Pirmohamed is a scholar working on Pharmacology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Munir Pirmohamed has authored 601 papers receiving a total of 34.5k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Pharmacology, 143 papers in Pharmacology and 116 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Munir Pirmohamed's work include Pharmacogenetics and Drug Metabolism (144 papers), Drug-Induced Adverse Reactions (114 papers) and Pharmaceutical studies and practices (78 papers). Munir Pirmohamed is often cited by papers focused on Pharmacogenetics and Drug Metabolism (144 papers), Drug-Induced Adverse Reactions (114 papers) and Pharmaceutical studies and practices (78 papers). Munir Pirmohamed collaborates with scholars based in United Kingdom, United States and Netherlands. Munir Pirmohamed's co-authors include Dean J. Naisbitt, Ana Alfirevic, Neil R. Kitteringham, B Kevin Park, Alasdair Breckenridge, Andrea Jorgensen, Mia Wadelius, Thomas Walley, James L. Maggs and Paula Williamson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Munir Pirmohamed

585 papers receiving 33.3k citations

Hit Papers

Drug repurposing: progress... 2001 2026 2009 2017 2018 2004 2004 2009 2001 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Drug repurposing: progress, challenges and recommendations
    2018 2.9k citations Sudeep Pushpakom, Munir Pirmohamed et al. profile →
  2. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
    2004 2.3k citations Munir Pirmohamed, Chris Green et al. BMJ profile →
  3. Phase I Clinical Trial of Oral Curcumin
    2004 1.0k citations Munir Pirmohamed et al. profile →
  4. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
    2009 732 citations B. Kevin Park, Munir Pirmohamed et al. profile →
  5. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
    2001 702 citations Munir Pirmohamed et al. PubMed profile →
  6. A Randomized Trial of Genotype-Guided Dosing of Warfarin
    2013 590 citations Munir Pirmohamed, Andrea Jorgensen et al. profile →
  7. Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
    2009 525 citations Munir Pirmohamed et al. PLoS ONE profile →
  8. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
    2011 473 citations Munir Pirmohamed et al. profile →
  9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
    2017 435 citations Munir Pirmohamed et al. profile →
  10. Pharmacogenomics: current status and future perspectives
    2023 131 citations Munir Pirmohamed profile →

Peers

Munir Pirmohamed
Teri E. Klein United States
Pertti J. Neuvonen Finland
Jos H. Beijnen Netherlands
Bruno H. Stricker Netherlands
Magnus Ingelman‐Sundberg Sweden
Howard L. McLeod United States
Leslie Z. Benet United States
Toine C. G. Egberts Netherlands
Dan M. Roden United States
Ann K. Daly United Kingdom
Teri E. Klein United States
Munir Pirmohamed
Citations per year, relative to Munir Pirmohamed Munir Pirmohamed (= 1×) peers Teri E. Klein

Countries citing papers authored by Munir Pirmohamed

Since Specialization
Citations

This map shows the geographic impact of Munir Pirmohamed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Munir Pirmohamed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Munir Pirmohamed more than expected).

Fields of papers citing papers by Munir Pirmohamed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Munir Pirmohamed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Munir Pirmohamed. The network helps show where Munir Pirmohamed may publish in the future.

Co-authorship network of co-authors of Munir Pirmohamed

This figure shows the co-authorship network connecting the top 25 collaborators of Munir Pirmohamed. A scholar is included among the top collaborators of Munir Pirmohamed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Munir Pirmohamed. Munir Pirmohamed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jorgensen, Andrea, et al.. (2024). Establishing reference ranges for circulating biomarkers of drug‐induced liver injury in healthy human volunteers 1. British Journal of Clinical Pharmacology. 91(5). 1361–1369.
2.
Gardner, Joshua, Rebecca L. Jensen, Andrew Gibson, et al.. (2024). Glycolysis: An early marker for vancomycin‐specific T‐cell activation. Clinical & Experimental Allergy. 54(1). 21–33. 3 indexed citations
3.
Evans, A.G., et al.. (2023). Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis. Frontiers in Genetics. 14. 1100352–1100352. 18 indexed citations
4.
Gibson, Andrew, Matthew S. Krantz, Eric Mukherjee, et al.. (2023). Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. Journal of Allergy and Clinical Immunology. 151(2). 289–300.e4. 42 indexed citations
5.
Wong, David, Lauren Walker, Iain Buchan, et al.. (2023). Combinations of medicines in patients with polypharmacy aged 65–100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions. PLoS ONE. 18(2). e0281466–e0281466. 9 indexed citations
6.
Olsson‐Brown, Anna, Vincent Yip, Lorenzo Ressel, et al.. (2022). TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis. Journal of Investigative Dermatology. 143(6). 1023–1030.e7. 16 indexed citations
7.
Asiimwe, Innocent G., Sudeep Pushpakom, Richard M. Turner, et al.. (2022). Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials. British Journal of Clinical Pharmacology. 88(8). 3577–3599. 11 indexed citations
8.
Fontana, Vanessa, Richard M. Turner, Ben Francis, et al.. (2022). Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol. Pharmacogenomics and Personalized Medicine. Volume 15. 249–260. 6 indexed citations
9.
Asiimwe, Innocent G., Sudeep Pushpakom, Richard M. Turner, et al.. (2021). Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 87(12). 4534–4545. 13 indexed citations
10.
Oussalah, Abderrahim, Vincent Yip, Cristobalina Mayorga, et al.. (2020). Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper. Allergy. 75(5). 1069–1098. 14 indexed citations
11.
Carr, Daniel F., Richard M. Turner, & Munir Pirmohamed. (2020). Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology. 87(2). 237–255. 19 indexed citations
12.
Ogese, Monday O., Adam Lister, Rosalind E. Jenkins, et al.. (2020). Characterization of Clozapine-Responsive Human T Cells. The Journal of Immunology. 205(9). 2375–2390. 13 indexed citations
13.
Turner, Richard M., Vanessa Fontana, Richard J. Fitzgerald, Andrew P. Morris, & Munir Pirmohamed. (2019). Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. British Journal of Clinical Pharmacology. 86(1). 62–74. 12 indexed citations
14.
Hope, William, Silvia Cicconi, Timothy Felton, et al.. (2019). Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. Antimicrobial Agents and Chemotherapy. 63(4). 19 indexed citations
15.
Bollegala, Danushka, et al.. (2018). Causality Patterns for Detecting Adverse Drug Reactions From Social Media: Text Mining Approach. JMIR Public Health and Surveillance. 4(2). e51–e51. 30 indexed citations
16.
Chaponda, Mas & Munir Pirmohamed. (2010). Hypersensitivity reactions to HIV therapy. British Journal of Clinical Pharmacology. 71(5). 659–671. 62 indexed citations
17.
Basit, Abdul W., David Gurwitz, Munir Pirmohamed, et al.. (2006). Invited Abstracts. Journal of Pharmacy and Pharmacology. 58(Supplement_1). A–91. 4 indexed citations
18.
Pirmohamed, Munir, et al.. (2004). Adverse drug reactions as cause of admission to hospital: Authors' reply. BMJ. 329(7463). 460.2–460.2. 11 indexed citations
19.
Naisbitt, Dean J., et al.. (2003). Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system.. PubMed. 8(2). 42–7. 15 indexed citations
20.
Brown, Cary A., et al.. (1997). Nurses' confidence in caring for patients with alcohol-related problems.. PubMed. 13(2). 83–6. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teri E. Klein Breakdown of academic impact, for papers by Pertti J. Neuvonen Breakdown of academic impact, for papers by Jos H. Beijnen Breakdown of academic impact, for papers by Bruno H. Stricker Breakdown of academic impact, for papers by Magnus Ingelman‐Sundberg Breakdown of academic impact, for papers by Howard L. McLeod Breakdown of academic impact, for papers by Leslie Z. Benet Breakdown of academic impact, for papers by Toine C. G. Egberts Breakdown of academic impact, for papers by Dan M. Roden Breakdown of academic impact, for papers by Ann K. Daly
Rankless by CCL
2026